MRKMerck Sharp & Dohme LLCRunning, no new patients
Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)
Breast Cancer
2Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.9
5 insiders sold shares within a month
Since Aug 13, 2026 · was worth 5, fading over time
Worry score2
Score over time
- Stage
- Phase 3
- Patients
- 1,240 (planned)
- Started
- Dec 27, 2018
- Main results expected
- Jan 24, 2031
- Fully finished
- Jan 24, 2031
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Pathological Complete Response (pCR) Rate Using the Definition of ypT0/Tis ypN0
Measured over: Up to approximately 7 months (Time of surgery)
Event-Free Survival (EFS)
Measured over: Up to approximately 12 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.9, since 2026-08-13, fades (half-life)
Raw record changes
- none yet
Trial ID NCT03725059 · record last updated 2025-07-11 · checked 2026-11-09 15:47 UTC